Literature DB >> 4336483

The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients.

J Denham, L Adamson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4336483     DOI： 10.1111/j.1600-0447.1971.tb03699.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN： 0001-690X            Impact factor:   6.392


× No keyword cloud information.
  6 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Treatment of chronic schizophrenia.

Authors:  D A Johnson
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

3.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09

4.  Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

Authors:  S R Hirsch; R Gaind; P D Rohde; B C Stevens; J K Wing
Journal:  Br Med J       Date:  1973-03-17

Review 5.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 6.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.